Aclaris Therapeutics (ACRS) EBITDA (2014 - 2026)

Aclaris Therapeutics' EBITDA history runs 13 years deep, the most recent figure standing at -$20.4 million for Q1 2026.

• In Q1 2026, EBITDA fell 38.41% year-over-year to -$20.4 million; the TTM figure through Mar 2026 stood at -$70.1 million (up 45.85% YoY), while the FY2025 annual figure was -$64.4 million, up 51.15% from the prior year.
• EBITDA was -$20.4 million for Q1 2026 at Aclaris Therapeutics, down from -$19.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$468000.0 in Q4 2023 to a low of -$96.9 million in Q4 2024.
• Historically, EBITDA has averaged -$23.1 million across 5 years, with a median of -$19.8 million in 2025.
• The sharpest annual moves came in 2023 and 2024: EBITDA jumped 98.27% in 2023, then sank 20601.28% in 2024.
• A 5-year view of EBITDA shows it stood at -$27.1 million in 2022, then surged by 98.27% to -$468000.0 in 2023, then tumbled by 20601.28% to -$96.9 million in 2024, then jumped by 79.58% to -$19.8 million in 2025, then declined by 3.18% to -$20.4 million in 2026.
• The last three EBITDA figures came in at -$20.4 million (Q1 2026), -$19.8 million (Q4 2025), and -$14.5 million (Q3 2025), per Business Quant data.